By Marie Rosenthal
The FDA approved a new indication for bosutinib (Bosulif, Pfizer) to include adults with newly diagnosed chronic phase, Philadelphia chromosome–positive chronic myelogenous leukemia (Ph+ CML).
Bosutinib is a tyrosine kinase inhibitor (TKI) that inhibits the Bcr-Abl kinase that promotes CML; it is also an inhibitor of Src family kinases.
The approval was based on data from BFORE (Bosutinib trial in First line chrOnic myelogenous leukemia tREatment), a